Protagonist Therapeutics, Inc. (PTGX) Q3 2017 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Up 0.27%

Protagonist Therapeutics reported a loss per share of $0.29, which was in line with expectations, but no revenue figures were disclosed. The stock reacted positively, increasing by 0.27%. This slight uptick may reflect investor confidence in the company's ongoing clinical programs despite the lack of specific guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.29	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized the importance of ongoing clinical trials. They did not offer specific guidance for future performance.

Management did not provide specific guidance for future quarters.

The focus remains on advancing clinical programs.

Protagonist Therapeutics Misses on EPS, Stock Up 0.27%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Up 0.27%

Key numbers

Management commentary